Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. is an American life sciences company that provides the preclinical research tools, laboratory models, and testing services that pharmaceutical and biotechnology companies rely on to advance drug candidates from discovery through regulatory approval, generating $4.02 billion in revenue in fiscal 2025. The company is the largest pure-play preclinical contract research organization in the world, operating across three segments: Discovery and Safety Assessment (DSA), which conducts the toxicology and safety studies required before a drug can enter human trials; Research Models and Services (RMS), which breeds and sells the laboratory animals — particularly non-human primates — used in those studies; and Manufacturing Solutions, which provides quality-control testing for biologic drugs already in production.

This is a story about a franchise whose market is pricing in disruption risk that management and the underlying science do not yet support, at a moment when cyclical demand is visibly turning. Charles River's stock has fallen roughly 55% from its 2021 peak of over $400 per share, driven by a biopharma spending slowdown in 2024–2025 and, more recently, an acute bout of AI anxiety as investors question whether machine-learning-driven drug discovery could reduce the need for animal-based preclinical testing. The file turns on a single question: whether the demand recovery visible in DSA bookings — net book-to-bill improved from 0.82x in Q3 2025 to 1.12x in Q4 and 1.04x in Q1 2026 — translates into durable revenue growth and operating leverage before the AI debate moves from speculation to something that actually changes client behavior.

The bull case does not require dismissing the AI risk entirely; it requires believing that the preclinical outsourcing model is stickier and more regulated than the market currently assumes, and that a company generating over $500 million in annual free cash flow with a vertically integrated NHP supply chain and a new CEO focused on efficiency can compound earnings at a mid-single-digit rate even in a flat revenue environment. The bear case requires believing that the best quarter of biotech funding in history will not translate into study starts, and that AI will disrupt a regulatory paradigm that has not materially changed in decades — both of which are possible but neither of which is priced in at 17x trough earnings.